Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 times the institutional ULN (unless elevated secondary to lymphomatous involvement of the liver, in which case the AST/ALT must be =< 5 times the institutional ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no greater than 1.5 times the ULN
Participants must have total bilirubin less than or equal to 1.5 times the upper limit of normal (ULN), and aspartate aminotransferase and alanine aminotransferase less than or equal to 2.5 times ULN.
Adequate liver function (total bilirubin ? 1.5 times the ULN, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 times ULN
Within 30 days prior to enrollment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) no greater than 1.5 times the ULN
Alanine aminotransferase (ALT) < 5 times ULN
Serum alkaline phosphatase, alanine aminotransferase, and aspartate aminotransferase ?2 times the upper limit of normal (ULN); ? 5 times ULN if there is liver or bone involvement.
Hepatic: Bilirubin ?1.5 times upper limits of normal (ULN), alanine aminotransferase (ALT) ? 3.0 times ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times ULN
Adequate hepatic function, with bilirubin < 2 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times ULN
Aspartate aminotransferase (AST) > 5 times the upper limit of normal (ULN) or alanine aminotransferase (ALT) > 5 times ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 × institutional ULN (patients with hepatic metastases must have AST/ALT ?5 times ULN).
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 times the ULN; if liver metastases are present, then ? 5 times the ULN is allowed.
Alanine aminotransferase (ALT) greater than 2.0 times the ULN in the absence of known hepatic metastases
AST (aspartate aminotransferase) and ALT (alanine aminotransferase) =< 3 times ULN (measured within 28 days of registration)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) if no hepatic metastasis =< 2.5 times x ULN
Alanine aminotransferase (ALT) < 2.5 times upper limit of normal (ULN) or ALT < 5.0 times ULN in the presence of liver metastases
Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ?2.5 times the upper limit of normal (ULN), or ?5 times the ULN for patients with liver metastases;
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) > 2.5 times ULN at the time of screening
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 times ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 times ULN or =< 5 times ULN if patient has documented liver metastases
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 times ULN or < 5 times ULN if patient has documented liver metastases
Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) =< 3.5 times ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times the ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULN (=< 5.0 x ULN if due to leukemic involvement)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times ULN
Alanine aminotransferase (ALT) =< 3 times the ULN
alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 times ULN.
EXCLUSION CRITERIA FOR ENROLLMENT: AST (aspartate aminotransferase)/ALT (alanine aminotransferase) > 3 times the ULN
EXCLUSION CRITERIA FOR ADDITIONAL PTCy-MILs INFUSION AT RELAPSE: AST (aspartate aminotransferase)/ALT (alanine aminotransferase) > 3 times the ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 times above the ULN, ALT and AST can be < 5 times ULN if patients have hepatic involvement
Within 21 days prior to C1D1: Aspartate aminotransferase (AST) < 2.5 times ULN and alanine aminotransferase (ALT) < 2.5 times ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 times ULN
Hepatic enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 2.5 times the institutional ULN
Alanine aminotransferase (ALT) =< 2 times the ULN or aspartate aminotransferase (AST) =< 2 times the ULN; these values must be obtained within four weeks before protocol entry
Total bilirubin >1.5 times the upper limit of normal (ULN) or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ? 2.5 X ULN at screening
Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.5 times ULN
Alanine aminotransferase (ALT) =< 2.5 times ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, ALT =< 2.5 times ULN is acceptable
Aspartate transaminase AST (SGOT) and alanine aminotransferase ALT (SGPT) =< 2.5 times the ULN except in patients with hepatic metastases for whom AST and ALT must be < 5.0 times the ULN
Have serum aspartate aminotransferase (AST) > 5 times upper limit of normal (ULN) at screening, or serum alanine aminotransferase (ALT) > 5 times ULN at screening, or total bilirubin >= 3.0 x ULN at screening (except for documented Gilbert's syndrome), by local or central lab. Subjects with biopsy confirmed CMV hepatitis will not be excluded from study participation despite AST or ALT > 5 times ULN at screening.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels >= 2.5 times the ULN or >= 5 times the ULN if liver metastases are present
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 times ULN in subjects without liver metastases or =< 5.0 times ULN in subjects with liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN
Serum/plasma alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ?2 times the upper limit of normal (ULN); ?5 times ULN if there is liver or bone involvement.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< to 2.5 times the ULN if no liver metastases; for patients with known liver metastases, AST and ALT must be =< to 5 times the ULN
Serum/plasma alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ?2 times the upper limit of normal (ULN); ? 5 times ULN if there is liver or bone involvement.
Serum alanine aminotransferase < 3 times the upper limit of normal (ULN); Note: If elevated liver enzymes are related to disease alanine aminotransferase (ALT) should be < 5 times ULN
Hepatic: Bilirubin 1.5 times upper limits of normal (ULN), alanine aminotransferase (ALT) and aspartate transaminase (AST) 3.0 times ULN. For participants with tumor involvement of the liver, AST and ALT equaling ?5.0 times ULN are acceptable. Alkaline phosphatase ?5.0 times ULN for participants with tumor involvement of the bone is acceptable.
Adequate hepatic function defined as: total bilirubin ?2.0 times the institutional ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.5 times the institutional ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times the ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 times the ULN, unless subjects have liver metastasis, in which case both AST and ALT must be less than or equal to 5 times the ULN
AST (aspartate aminotransferase) and ALT (alanine aminotransferase) =< 3 times ULN
Alanine aminotransferase (ALT) < 2.5 times ULN
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2.5 times ULN
Alanine aminotransferase (ALT) < 2.5 times ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, ALT < 5.0 times ULN is acceptable
Serum alanine aminotransferase or aspartate aminotransferase > 3 times ULN
Alanine aminotransferase (ALT) =< 2.5 times ULN*
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 times ULN
Patient has poor liver function (> 2.5 times normal of alanine aminotransferase [ALT]/aspartate aminotransferase [AST]) suggestive of cirrhosis or steatohepatitis
Serum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN Note: If elevated liver enzymes, above the ULN, are related to disease; contact medical monitor to discuss.
Hepatic enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 2.5 times the institutional ULN
Alanine aminotransferase (ALT) =< 2.5 times ULN
Hepatic enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 2.5 times the institutional ULN
Alanine aminotransferase (ALT) =< 2.5 times ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 times ULN for participants without liver metastases, or ?5 times ULN in the presence of liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 times ULN for subjects without liver metastases, or ? 5 times ULN in the presence of liver metastases
Alanine aminotransferase and aspartate aminotransferase </= 3 times the ULN
Patients must have adequate hepatic function with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULN within one week prior to treatment
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 times the ULN for the reference lab
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 times ULN
Subject has total serum bilirubin ?1.5 times the upper limit of normal (ULN),serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 3 times ULN, or albumin ? 3.0 g/dL at Screening.
Alanine aminotransferase (ALT) < 2.5 times ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, ALT < 5.0 times ULN is acceptable
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) </=2.5 times ULN (</=5 times ULN for subjects with liver involvement of their cancer)
Serum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN. Note: If elevated liver enzymes are related to disease; contact medical monitor to discuss.
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 times the ULN.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels less than 1.5 times ULN at study entry
Adequate hepatic function, with bilirubin < 2 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.5 times ULN
Adequate hepatic function within 21 days prior to randomization, with bilirubin < 1.5 times the upper limit of normal (ULN), and aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 times the ULN.
Serum alanine aminotransferase < 2.5 times the ULN.
Aspartate aminotransferase (AST) or alanine transaminase (ALT) > 5 times ULN
Serum alanine aminotransferase or aspartate aminotransferase < 3 times the ULN. Note:If elevated liver enzymes are related to disease; contact medical monitor to discuss.
Liver enzymes (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) >= 2.5 times the upper limits of normal (ULN) 14 days prior to study enrollment
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN
Liver function: total bilirubin ? 1.5 times the upper limit of normal (ULN) of each institution, aspartate aminotransferase and alanine aminotransferase ? 3 times the ULN range of each institution.
Hepatic: bilirubin ?1.5 times upper limits of normal (ULN), alanine aminotransferase (ALT) and aspartate transaminase (AST) ?3.0 times ULN. For participants with tumor involvement of the liver, AST and ALT equaling ?5.0 times ULN are acceptable. Alkaline phosphatase ?5.0 times ULN for participants with tumor involvement of the bone is acceptable.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 times ULN (? 5 times ULN for patients with impaired liver function due primary tumor or metastatic disease)
Serum/plasma alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2 times the upper limit of normal (ULN); ?5 times ULN if there is liver or bone involvement.
Within 14 days prior to registration: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (AST and/or ALT =< 5 x ULN for patients with liver involvement)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN), unless suspected leukemic involvement of the liver
Aspartate aminotransferase (AST) ? 2.5 x ULN; alanine aminotransferase (ALT) ? 2.5 x ULN; AST/ALT < 5 x ULN if liver involvement
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBILI) each < 3×ULN; however, ALT, AST, and TBILI each ? 5×ULN is acceptable if the elevation is considered due to PTLD involvement of the liver.
Alanine aminotransaminase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN, unless clearly due to disease involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 × the upper limit of normal (ULN) (=< 5 × ULN if considered due to primary or metastatic liver involvement)
Aspartate aminotransferase (AST) =< 3 x ULN unless evidence of the direct liver involvement by lymphoma - then =< 5 x ULN obtained =< 14 days prior to registration
Aspartate aminotransferase/alanine aminotransferase (AST/ALT) ? 3 upper limit of normal (ULN). In cases with liver involvement ALT/ AST ? 5× ULN.
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 10 upper limit of normal (ULN) (unless elevated ALT/AST is attributed to leukemia or lymphoma involvement of the liver, in which case this criterion will be waived and not disqualify a patient)
Aspartate and alanine aminotransferase (AST and ALT) =< 2.5 x ULN; =< 5.0 x ULN if there is liver involvement secondary to tumor
Alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >3 x ULN for patients without tumor involvement of the liver or >5 x ULN for patients with tumor involvement of the liver.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.5 x the upper limit of normal (ULN), if no liver involvement or ?5 x ULN with liver involvement
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 3 x the ULN for the reference lab (=< 5 x the ULN if there is evidence of hepatic involvement by malignant disease)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN with the following exception: patients with liver involvement: AST and/or ALT =< 5 x ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (unless due to liver involvement)
Alanine aminotransferase (ALT) =< 2.5 x ULN unless demonstrated lymphoma involvement of the liver, performed within 14 days prior to day 1 of protocol therapy
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 2.5 institutional ULN or, in the case of liver involvement by the primary disease AST/ALT ? 5 x ULN
STUDY TREATMENT: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 × ULN within 14 days prior to the first study treatment with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 × ULN.
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 3x the institutional ULN, except for people with liver involvement by their lymphoma, who may be included if AST/ALT ? 5x the institutional ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times the ULN (=< 5 x ULN for patients with liver involvement)
Obtained =< 14 days prior to registration: Alanine aminotransferase (ALT) =< 2 x ULN (=< 5 x ULN for patients with liver involvement)
Serum alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 10 upper limit of normal (ULN) (unless elevated ALT/AST is associated with leukemia or lymphoma involvement of the liver, in which case this criterion will be waived and not disqualify a patient)
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) < 3x ULN unless considered due to leukemic involvement
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN with the exception that patients with liver involvement: AST and/or ALT =< 5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional ULN or, in the case of liver involvement by the primary disease AST/ALT =< 5 x ULN
Within 14 days prior to cycle 1 day 1 of treatment: Aspartate aminotransferase (AST) =< 2.5 x ULN (5.0 x ULN if liver involvement)
Within 14 days prior to cycle 1 day 1 of treatment: Alanine aminotransferase (ALT) =< 2.5 x ULN (5.0 x ULN if liver involvement)
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) or =< 5 x ULN if related to leukemic involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN, unless clearly due to disease involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Within 14 days prior to the first study treatment (cycle 1, day 1): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 x ULN
FULL STUDY INCLUSION CRITERIA: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for patients with liver involvement of their cancer)
To be performed within 10 business days prior to day 1: Alanine aminotransferase (ALT) =< 3 x ULN unless demonstrated Hodgkin lymphoma involvement of the liver
Aspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) if no liver involvement or =< 5 x the ULN if documented liver involvement
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal (ULN), except for people with liver involvement by their lymphoma, who may be included if AST/ALT =< 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN, unless clearly due to disease involvement
Liver function abnormality as defined by total bilirubin >1.5 × ULN or aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >2.5 × ULN (except for subjects with liver involvement, who can have AST/ALT >5 × ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x ULN if patients have liver involvement with MM)
Aspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x the ULN unless considered due to organ leukemic involvement
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) =< 3 x upper limit of normal (ULN) or < 5 x ULN if related to leukemic involvement
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 2.5 X ULN, or for subjects with liver involvement AST and/or ALT > 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver involvement
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT ) < 2.5 x the upper limits of institutional normal (=< 5 x ULN for patients with liver involvement of leukemia)
Alanine and aspartate transaminases (ALT and AST) =< 2.5 times the ULN (=< 5 x ULN for patients with liver involvement)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN; =< 5 x ULN if due to lymphoma involvement, without use of growth factor support for 1 week
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5.0 x ULN for patients with liver involvement of their cancer)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x the upper limits of institutional normal (=< 5 x ULN for patients with suspected liver involvement of leukemia)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN if there is evidence of hepatic involvement by malignant disease)
Alanine aminotransferase (ALT) and aspartate aminotransferease (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x the ULN if no liver involvement, or =< 5 x the ULN with liver involvement
Aspartate aminotransferases (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 times ULN (unless elevated due to secondary lymphomatous involvement of the liver)
Total bilirubin ?1.5 × the upper limit of normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3 × ULN. If the liver has tumor involvement, AST and ALT <5 × ULN.
Aspartate aminotransferase (AST) =< 3 x ULN unless evidence of the direct liver involvement by lymphoma – then =< 5 x ULN
SUB-PROTOCOL AIM A: Aspartate transaminase (AST); alanine aminotransferase (ALT) =< 1.5 x ULN; NOTE: if subject has tumor involvement in the liver =< 5 X ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Aspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within 2.5 x ULN, or =< 5.0 x ULN for patients with documented hepatic involvement
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN; =< 5 if due to lymphoma involvement
Aspartate aminotransferase (AST) ? 2.5 x ULN; alanine aminotransferase (ALT) ? 2.5 x ULN; AST/ALT < 5 x ULN if liver involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Aspartate transaminase (AST) and alanine aminotransferase (ALT) =< 1.5 x ULN (=< 5 x ULN for patients with liver involvement)
Total bilirubin 1.5 × the upper limit of institutional normal (ULN) and alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 3 × ULN. If the liver has tumor involvement, AST and ALT <5 × ULN are acceptable.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) obtained =<14 days prior to randomization
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (less than or equal to 5 x upper limit of normal for patients with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.0 x ULN if no liver involvement or =< 4 x the ULN if known liver involvement
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 times upper limit of normal (ULN); (for patients with liver involvement: AST and ALT =< 2.5 ULN)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Obtained within 14 days prior to the first study treatment (cycle 1, day 1); aspartate aminotransferase measurement (AST) and alanine aminotransferase measurement (ALT) ? 3.0 x ULN with the following exception:\r\n* Patients with liver involvement: AST and/or ALT ? 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN if no liver involvement, or =< 5 x ULN with liver involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN if no liver involvement, or =< 5 X ULN with liver involvement
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5.0 x ULN for patients with liver involvement of their cancer)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 ULN (obtained within 14 days prior to the first study treatment [course 1, day 1]) with the following exception:\r\n* Patients with liver involvement: AST and/or ALT =< 5 x ULN
Alanine aminotransferase and aspartate aminotransferase < 2.5 of the ULN (< 5 x of ULN for subjects with liver involvement of their cancer)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5.0 x ULN if considered to be due to leukemic involvement)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN (? 5 x ULN for subjects with hepatic involvement with tumor)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Aspartate aminotransferase (AST) and alanine aminotransaminase (ALT) =< 3 x ULN for the institution (=< 5 x ULN is acceptable if liver has tumor involvement)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN, unless due to liver involvement with lymphoma
Serum aspartate aminotransferase (AST) or serum alanine aminotransferase (ALT) levels must be =< 2.5 x ULN, or =< 5 X ULN for patients with liver involvement by lymphoma
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN (? 5 x ULN for subjects with liver involvement of their cancer)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5.0 ULN if hepatic involvement is present as determined by the investigator
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN if no liver involvement, or =< 5 x ULN with liver involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN if no liver involvement, or =< 5 x ULN with liver involvement
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 X institutional ULN (unless demonstrated Hodgkin lymphoma involvement of the liver)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 2.5 times the ULN (>= 5 x ULN for patients with liver involvement)
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 the upper limit of normal (ULN); < 5 ULN if there is liver involvement secondary to the tumor
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal (ULN), except for people with liver involvement by their lymphoma, who may be included if AST/ALT =< 5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 3 x ULN (5 x ULN for those with lymphoma involvement of the liver)
Alanine transaminase (alanine aminotransferase [ALT]) =< 2 x upper normal limit (ULN) (in the expansion cohort, patients with known liver involvement may have ALT =< 5 x ULN); aspartate aminotransferase (AST) =< 2 x ULN (in the expansion cohort, patients with known liver involvement may have AST =< 5 x ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN in the absence of known metastatic involvement of the liver or AST and ALT =< 5.0 x ULN if there is metastatic liver involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.5 x ULN if no liver involvement or ?5 x ULN with liver involvement.
Alanine aminotransferase (ALT) =< 3 x ULN
Serum alanine aminotransferase (ALT) < 2.5 x ULN
Alanine aminotransferase (ALT) =< 3.0 X ULN, within 14 days of registration
Alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT [SGPT]) ?2.5 × the ULN;
Alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) =< 2 x ULN OR if hepatic involvement by lymphoma: ALT =< 5 x ULN
Alanine aminotransferase (ALT) < 2 x institutional ULN within 14 days of enrollment to trial
Alanine aminotransferase (ALT) =< 3.0 X ULN
alanine aminotransferase (ALT) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
Alanine aminotransferase (ALT) =< 1.5 x institutional ULN
Within 14 days of the first dose of study drug: Alanine aminotransferase (ALT) =< 3 x ULN
Alanine aminotransferase (ALT) level =< 2.5 × ULN.
Alanine aminotransferase (ALT) < 3 x ULN, unless due to the underlying leukemia approved by the PI
Alanine aminotransferase (ALT) ? 3 x ULN for age, unless elevation is due to leukemic infiltration
Alanine aminotransferase (ALT) ? 3.0 x ULN (unless considered due to leukemic organ involvement)
Alanine aminotransferase (ALT) > 45 U/L
Alanine aminotransferase (ALT) =< 3 x ULN.
Alanine aminotransferase (ALT) level =< 2.5 x ULN
Alanine aminotransferase (ALT) ? 1.5 x ULN
alanine aminotransferase (ALT) <= 3.0 x ULN*
Alanine aminotransferase (ALT) =< 2.5 x ULN
To be performed within 14 days prior to day 1 of protocol therapy: alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) =< 3 x ULN.
Alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN within 14 days of study registration.
Alanine aminotransferase (ALT) (SPGT) is ? 3 X ULN for age
Alanine aminotransferase (ALT) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
Alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) =< 3 x ULN.
ALT (alanine aminotransferase) =< 2 x ULN
Alanine aminotransferase (ALT) =< 3 x ULN
Obtained within 14 days of randomization: Alanine aminotransferase (ALT) =< 3 x ULN
alanine aminotransferase (ALT) ? 3.0 × ULN*
Alanine aminotransferase (ALT) =< 2.5 x ULN prior to biopsy
Alanine aminotransferase (ALT) =< 2.5 x ULN
LYMPHODEPLETION: Alanine aminotransferase (ALT) =< 3.0 x ULN, obtained within 72 hrs prior to procurement
Within 14 days prior to planned start of treatment: Alanine aminotransferase (ALT) =< 2 x ULN
Alanine aminotransferase (ALT) =< 1.5 x ULN for the laboratory
Alanine aminotransferase (ALT) < 3 x ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) =< 3.0 x ULN
Alanine aminotransferase (ALT) < 1.5 x ULN
Alanine aminotransferase (ALT) =< 2 x ULN for the laboratory
Alanine transaminase (alanine aminotransferase [ALT]) > 3.0 x ULN
Alanine aminotransferase (ALT) =< 2.5 X ULN
Alanine aminotransferase (ALT) < 2.5 x ULN (3 x ULN for subjects on chronic anticonvulsive therapies known to increase transaminases).
Alanine aminotransferase (ALT) =< 3 x ULN for the laboratory, except in the presence of known hepatic metastasis, wherein the ALT may be =< 5 x ULN
Within 3 months of registration: Alanine aminotransferase (ALT) =< 2.5 x ULN
Within 14 days prior to study entry: Alanine aminotransferase (ALT) =< 3 x ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN for the laboratory
Alanine aminotransferase (ALT) =< 3.5 x ULN
AT THE TIME OF INFUSION: Alanine aminotransferase (ALT) ? 5 x normal
Alanine aminotransferase (ALT) =< 2.5 x ULN
Within 2 weeks of enrollment: Alanine aminotransferase (ALT) =< 3 x normal range
Alanine aminotransferase (ALT) =< 189 IU/L
Alanine aminotransferase (ALT) =< 3 x ULN unless considered due to leukemic involvement
Alanine aminotransferase (ALT) =< 2 x ULN
Alanine aminotransferase (ALT) > 3 x ULN
Alanine aminotransferase (ALT) ?110 units per Liter (U/L). For the purpose of this study, the ULN for ALT is 45 U/L
Alanine aminotransferase (ALT) > 2.5 X ULN or cirrhosis
Alanine aminotransferase (ALT) within the reference range during screening evaluation
Alanine aminotransferase (ALT) > 5 x ULN
To be performed within 14 days prior to day 1 of protocol therapy: alanine aminotransferase (ALT) =< 3 x ULN\r\n* If hepatic involvement by lymphoma: ALT =< 5 x ULN
Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Alanine aminotransferase (ALT) =< 2 x ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN for the laboratory
Alanine aminotransferase (ALT) =< 3 x ULN
Alanine aminotransferase (ALT) < 1.5 X ULN; patients with Gilbert's disease are exempt from this criteria
Alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) =< 3 x ULN for the laboratory
Alanine aminotransferase (ALT) =< 2.5 x ULN without, and =< 5 x ULN with hepatic metastasis
Alanine aminotransferase (ALT) ? 2 x ULN
Alanine aminotransferase (ALT) =< 3 x ULN within 14 days prior to study registration
Alanine aminotransferase (ALT) =< 2.5 x ULN without, and =< 5 x ULN with hepatic metastasis
Alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase less than or equal to 3 x ULN
Alanine aminotransferase (ALT) =< 3 x ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) =< 1.5 X ULN
Alanine aminotransferase (ALT) > 2.5 x ULN
and alanine aminotransferase (ALT) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
alanine aminotransferase (ALT) less than or equal to 2.5 × ULN*
Alanine aminotransferase (ALT) ? 1.5 x ULN unless there is hepatic involvement, then 3 x ULN
Alanine aminotransferase (ALT) ? 5 × institutional ULN
Within 30 days prior to initiation of protocol treatment: Alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) =< 3 x ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) =< 1.5 x ULN
Alanine aminotransferase (ALT) < 5 x ULN age
Alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) =< 1.5 x ULN
Alanine aminotransferase (ALT) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
Alanine aminotransferase > 100 IU/L
Alanine aminotransferase (ALT) ?3 × ULN
Alanine aminotransferase (ALT) < 3 x ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5.0 x ULN if considered due to leukemic involvement)
Alanine aminotransferase (ALT) < 300 IU/ml
Alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) =< 1.5 X ULN
Alanine aminotransferase (ALT) =< 2.5 x the ULN (in the absence of hepatic involvement of tumor)
Alanine aminotransferase (ALT) ?3xULN
Alanine aminotransferase (ALT) =< 5 x ULN for age, unless the elevation is disease-related
Alanine aminotransferase (ALT) =< 3 x ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) > 3 x ULN for the laboratory
Serum alanine aminotransferase ? (ALT) 2.0 x ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) =< 1.8 X ULN
Alanine aminotransferase (ALT) =< 1.5 x ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase =< 40 IU/dL
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN within 30 days of day 1 of study
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 2.5 x institutional ULN
Alanine (ALT) or aspartate (AST) aminotransferase > 1.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN, within 4 weeks of randomization
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the institutional ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3X the institutional ULN
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 1.5 X ULN
Alanine aminotransaminase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN.
In case alkaline phosphatase is >2.5 x ULN patients are eligible for inclusion if aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 1.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at most 3 x ULN.
Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) < 2.5 × ULN; serum bilirubin < 1.5 × ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 × ULN
Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 2.5 x institutional ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN within 7 days before the first dose of cabozantinib
Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) < 3 X ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 × ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 10 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × institutional ULN.
Alanine aminotransferase (ALT) =< 3 x ULN, aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN
Aspartate aminotransferase (ALT) and alanine aminotransferase (AST) =< 3 x ULN
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
PHASE I: Transaminases (aspartate aminotransferase [AST] and/or alanine aminotransferase [ALT]) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
Alanine aminotransferase and aspartate aminotransferase ? 3 x ULN.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) up to 2.5 x upper limits of normal (ULN).\r\n* Patients known to have Gilbert’s disease may be eligible with AST and ALT up to 5 x ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x the ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN within four weeks of enrollment
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x the ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3.0 x institutional ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< ULN
Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) > 2.5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 3 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x institutional ULN.
Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x ULN unless deemed to be related to underlying leukemia.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 × ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 ULN (within 14 days of PET imaging)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 X ULN
An aspartate aminotransferase (AST) level =< 2.5 x ULN, and an alanine aminotransferase (ALT) level =< 2.5 x ULN.
STRATUM B: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN; for the purposes of eligibility the ULN of ALT and AST is 45 U/L
STRATUM C: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN; for the purposes of eligibility, the ULN of ALT and AST is 45 U/L
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
COHORT 1: HORMONE RECEPTOR POSITIVE BREAST CANCER: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 3 X ULN
Aspartate aminotransferase or alanine aminotransferase =< 2.5 x ULN.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3.0 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULN
Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x the laboratory ULN
Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.0 x ULN or
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x ULN.
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 X the ULN
Within 3 days before the first dose of study drug: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate and Alanine Aminotransferase (AST and ALT) < 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN
Aspartate aminotransferase and alanine aminotransferase concentrations of =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Within 7 days before the first dose of study treatment: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x the ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 X ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN unless believed due to leukemic infiltration
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN
Alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) ?2.5 × ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN
Patients are eligible with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN, within 30 days before study registration
Alanine aminotransferase and aspartate aminotransferase =< 2.5 X ULN except in patients with aspartate aminotransferase (AST)/alanine aminotransferase (ALT) elevation that is declared to be caused due to liver metastasis, they are allowed to be enrolled as long as < 5 x ULN
Aspartate and alanine aminotransferase (AST or ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN for all subjects
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x the laboratory ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x ULN
alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 × ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) less than 2.5 X institutional ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 ULN unless higher levels are related to leukemic infiltration
Aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT) ?3.0 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 × ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 3 X ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT): =< 3 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) > 5 X ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x ULN unless thought to be disease related
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3.0 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 5.0 x ULN for age
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Patients are eligible with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) =< 5 x ULN, within 14 day prior to registration
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 × ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULN and total bilirubin =< 2 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< to 2.5 X ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
PHASE I: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.0 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) less than or equal to 2.5 x ULN
Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) less than 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 6 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ? 3 x ULN.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >3 x ULN
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be less than or equal to (<=) 2.5*the ULN.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x the ULN prior to biopsy
Within 4 days prior to the first dose of cabozantinib: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN ^1
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 4x ULN, unless secondary to disease
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x the ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 x ULN
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) equal or less than 200 IU/ml for adults
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; and
Aspartate aminotransferase and alanine aminotransferase < 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 4 x normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 3 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 4x normal
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x normal
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 5 x normal
Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) > 1.5 × ULN.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3 x ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Serum AST (aspartate aminotransferase) and ALT (alanine aminotransferase) ? 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (repeat if more than 3 days before the first dose)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) <3 x ULN Inclusion Criteria unique to the ER+ve cohort:
Aspartate aminotransferase and alanine aminotransferase less than 5 × ULN for the institution
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN; NOTE: concomitant elevations in ALT/AST above 1.0 x ULN is not permitted
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?2.5x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULN
Aspartate aminotransferase and alanine aminotransferase ?2.5 × ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Within 14 days prior to the first study treatment (cycle 1, day 1): Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN.
Alanine aminotransferase/aspartate aminotransferase (ALT/AST) =< 5 x ULN.
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) less than 2.5 X institutional ULN
BLADDER: Clinical laboratory values at screening: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3.0 x ULN
Within 7 days before the first dose of cabozantinib: Alanine aminotransferase (ALT) and aspartate aminotransfearse (AST) =< 2.0 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN, within 28 days of day 0.
Within 10 days of treatment initiation: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Within 14 days of study registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase, alanine aminotransferase (AST, ALT) =< 3.0 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) greater than or equal to 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Transaminases (aspartate aminotransferase [AST] and alanine aminotransferase [ALT]) < 6 x institutional ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< grade 1
Alanine aminotransferase and aspartate aminotransferase =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) each < 1.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 10 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
Alanine aminotransferase (ALT) > 50 U/L or aspartate aminotransferase (AST) > 65 U/L
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 3.0 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase/alanine aminotransferase (AST/ALT) =< 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5.0 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x UNL unless related to primary disease
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN for the institution
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN within 14 days of enrollment
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN, within 2 weeks of the first dose of study treatment
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
Transaminase (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) > 20 x ULN based on age- and laboratory specific normal ranges
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN (if both tests are done, both results need to be =< 2.5 x ULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 x ULN (institutional)
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ?3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x ULN
Total bilirubin > 1.5 x ULN; and aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3.0 x ULN.
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x institutional ULN
AMKL PATIENTS: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x institutional normal
Aspartate aminotransferase (AST) =< 2.5 x ULN or alanine aminotransferase (ALT) =< 2.5 x ULN (Note, if both AST and ALT are done, both must be =< 2.5 x ULN) OR
Aspartate aminotransferase (AST) and/or Alanine Aminotransferase (ALT) superior to 3 x ULN.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <2.5*ULN.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 X ULN
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < or equal to 2.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 × ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN (values post biliary stenting allowed for eligibility)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 200 U/L
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 × ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = < 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULN
Alanine aminotransferase; and, Aspartate aminotransferase AST and ALT<=2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 * ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x institutional ULN unless it is related to the primary disease
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 X the ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x ULN
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 3.5 X ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >= 2.5 x ULN
COHORT A: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 3 x the laboratory ULN
Aspartate aminotransferase (AST) =< 2.5 x ULN, alanine aminotransferase (ALT) =< 2.5 x ULN
Adequate hepatic function, with aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< grade 3
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2 x ULN
Patients are eligible with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) and alkaline phosphatase must be within the range allowing for eligibility
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
Have normal serum transaminase values (aspartate aminotransferase [AST] and alanine aminotransferase [ALT])
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) >= 5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN for the institution
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3 x ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 5 X ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN; concomitant elevations in AST/ALT above 1.0 X ULN are not permitted
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.0 X ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x normal
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULN
Aspartate aminotransferase or alanine aminotransferase > 1.5 × ULN
Within 8 weeks of randomization: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3.0 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 1.5 X ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x normal
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
Aspartate and alanine aminotransferase (AST and ALT) =< 5 x ULN
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) ?3 × ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x ULN unless related to primary disease
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULN
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline phosphatase (ALP) ? 5 x ULN.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 5 x ULN, +/- 7 days from date of ICF signing
Serum alanine aminotransferase and serum aspartate aminotransferase (ALT/AST) =< 5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) must be =< 1.5 x ULN for the lab
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN
Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) > 1.5 x ULN concomitant with alkaline phosphatase > 2.5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) above 2.5X the ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal limits
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x UNL
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?5.0 × ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 5 x ULN for age
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 ×ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2x institutional ULN unless it is related to the primary disease
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) of =< 2 ULN
Alanine aminotransferase (ALT) =< 3 x ULN and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 × ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <=2.5xULN
Serum aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) >= 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 3.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 3 x institutional ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal range
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN, within 14 days prior to initiation of study drug
Cohort A: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 X ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN;
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
Had at least one liver function test (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) with normal results in the last year
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULN
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 200 IU/ml
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x ULN unless related to primary disease
Normal organ function tests including aspartate aminotransferase (AST) and alanine aminotransferase (ALT)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN
Alanine aminotransferase or aspartate aminotransferase >= 2.5 x ULN
Aspartate aminotransferase (AST, and alanine aminotransferase (ALT) =< 1.5 x ULN.
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) < 3 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN for institution
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN
Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ? 2.5xULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the institutional ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 200 U/L
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x institutional ULN
Known alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x ULRR or
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Alanine aminotransferase (ALT) < 1.5 x ULN, aspartate aminotransferase (AST) < 1.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (unless benign congenital hyperbilirubinemia)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x ULN
Hepatic enzymes (aspartate aminotransferase [AST], alanine aminotransferase [ALT]) =< 2.5 x ULN
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULN (unless determined by treating physician to be related to underlying malignancy)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 3 x ULN
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2.5 x ULRR
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) within 2 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x institutional ULN unless it is related to the primary disease
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN
Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) > 2.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN, completed within 2 weeks prior to start of protocol therapy
Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN.
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x institutional ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?5×ULN.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Have normal serum transaminase values (aspartate aminotransferase [AST] and alanine aminotransferase [ALT])
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN for the lab utilized
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN for all subjects
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) within the normal range at the screening visit
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) within normal limits
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 X ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be <=2.5*ULN.
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 X institutional UNL,
Aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) =< 3.0 X ULN, within 14 days of registration
Aspartate aminotransferase (AST) and/or ALT ? 2.5 × ULN
Aspartate aminotransferase (AST) < 5 times ULN
Aspartate aminotransferase (AST [SGOT]) ?2.5 × the ULN;
Aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) =< 2 x ULN OR if hepatic involvement by lymphoma: AST =< 5 x ULN
aspartate aminotransferase (AST) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
Aspartate aminotransferase (AST) =< 1.5 x institutional ULN
Aspartate aminotransferase (AST) =< 3 X ULN
INCLUSION - TREATMENT: Aspartate aminotransferase (AST) ? 5x
Within 14 days of the first dose of study drug: Aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) level =< 2.5 × ULN.
Aspartate aminotransferase (AST) < 3 x ULN unless due to the underlying leukemia approved by the PI
Aspartate aminotransferase (AST) ? 3.0 x ULN (unless considered due to leukemic organ involvement)
Aspartate aminotransferase (AST) greater than 2.0 times the ULN in the absence of known hepatic metastases
Aspartate aminotransferase (AST) > 45 U/L
Aspartate aminotransferase (AST) =< 3 x ULN.
Aspartate aminotransferase (AST) level =< 2.5 x ULN
Serum aspartate aminotransferase (AST) ?3 × ULN (Grade ?1).
Aspartate aminotransferase (AST) < 3 x ULN unless considered due to leukemic involvement
Aspartate aminotransferase (AST) ? 1.5 x ULN
aspartate aminotransferase (AST) <= 3.0 x ULN*
Aspartate aminotransferase (AST) =< 2.5 x ULN
To be performed within 14 days prior to day 1 of protocol therapy: aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) =< 3 x ULN.
Aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) =< 2.5 x ULN within 14 days of study registration.
Aspartate aminotransferase (AST) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
Aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with documented metastatic disease to the liver).
Aspartate aminotransferase (AST) within 2.5 x ULN unless there are liver metastases in which case, AST within 5 x ULN
Aspartate aminotransferase (AST) =< 3 x ULN.
Aspartate aminotransferase (AST) =< 2.0 x ULN
Aspartate aminotransferase (AST) within 2.5 x ULN unless there are liver metastases in which case, AST within 5 x ULN
Aspartate aminotransferase (AST) =< 5 x ULN
Aspartate aminotransferase (AST) =< 3 x ULN
Obtained within 14 days of randomization: Aspartate aminotransferase (AST) =< 3 x ULN
aspartate aminotransferase (AST) ? 3.0 × ULN*
Aspartate aminotransferase (AST) =< 2.5 x ULN prior to biopsy
Aspartate transaminase (aspartate aminotransferase [AST]) =< 2.5 x ULN
Aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) =< 2.5 x ULN (obtained within 28 days prior to first study treatment)\r\n* Subjects with documented liver metastases should have AST =< 5 x ULN
LYMPHODEPLETION: Aspartate aminotransferase (AST) =< 3.0 x ULN, obtained within 72 hrs prior to procurement
Aspartate aminotransferase (AST) and AST <3x institutional ULN within 7 days prior to starting the study drug.
Aspartate aminotransferase (AST) =< 1.5 x ULN for the laboratory
Aspartate aminotransferase (AST) < 3 x ULN
Aspartate aminotransferase (AST) =< 1.5 x ULN
Aspartate aminotransferase (AST) =< 2 x ULN for the laboratory
Aspartate transaminase (aspartate aminotransferase [AST]) > 3.0 x ULN
Aspartate aminotransferase (AST) =< 2.5 X ULN
Aspartate aminotransferase (AST) < 2.5 x ULN (3 x ULN for subjects on chronic anticonvulsive therapies known to increase transaminases).
PRIOR TO CELL PROCUREMENT: Aspartate aminotransferase (AST) ? 3 times ULN
Aspartate aminotransferase (AST) =< 3 x ULN for the laboratory, except in the presence of known hepatic metastasis, wherein the AST may be =< 5 x ULN
Aspartate aminotransferase =< 3 x ULN
Within 3 months of registration: Aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) =< 3 times the ULN
Within 14 days prior to study entry: Aspartate aminotransferase (AST) =< 3 x ULN
Any serum aspartate aminotransferase (AST) is allowed but serum AST =< 34 IU/L is strongly encouraged
Aspartate aminotransferase (AST) =< 2.5 x ULN for the laboratory
Aspartate aminotransferase (AST) =< 3.5 x ULN
TREATMENT: Aspartate aminotransferase (AST) < 5 × ULN
Aspartate aminotransferase (AST) =< 3 x ULN (must be within 7 days of MLA)
Aspartate aminotransferase (AST) =< 121 IU/L
Aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) > 3 x ULN
Aspartate aminotransferase (AST) < 5 x ULN
Aspartate aminotransferase (AST) < 3 times the ULN
Aspartate aminotransferase level (<=) 2.5* ULN, and
Aspartate aminotransferase (AST) within the reference range during screening evaluation
Aspartate aminotransferase (AST) > 5 x ULN
To be performed within 14 days prior to day 1 of protocol therapy: aspartate aminotransferase (AST) =< 3 x ULN\r\n* If hepatic involvement by lymphoma: AST =< 5 x ULN
Within 14 days prior to day 1 of protocol therapy unless otherwise stated: Aspartate aminotransferase (AST) =< 2 x ULN
At cycle 1 day 1 pre-dosing: Aspartate aminotransferase (AST) >= 2.5 x the ULN
Aspartate aminotransferase (AST) =< 2.5 x ULN for the laboratory
Aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) =< 2 x ULN
Aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) =< 3 x ULN for the laboratory
Aspartate aminotransferase (AST) < 2.5 x ULN of the institutional normal reference range
Aspartate aminotransferase (AST) must be =< 1.5 x ULN for the lab
Aspartate transaminase (aspartate aminotransferase [AST]) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastasis), obtained =< 21 days prior to registration
Aspartate aminotransferase (AST) ? 2.0 X ULN,
Aspartate aminotransferase (AST) ? 2 x ULN
Aspartate aminotransferase (AST) =< 3 x ULN within 14 days prior to study registration
Aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase less than or equal to 3 x ULN
Aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) < 5 x ULN
Aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) =< 1.5 X ULN
and aspartate aminotransferase (AST) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
Aspartate aminotransferase (AST) ? 1.5 x ULN unless there is hepatic involvement, then 3 x ULN
Aspartate aminotransferase (AST) =< 5 x ULN
Aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) =< 3 X ULN
Aspartate aminotransferase (AST) =< 1.5 x ULN
Aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) =< 2.5 x the ULN for age (in the absence of hepatic involvement of tumor)
Aspartate aminotransferase (AST) ? 2.5 × ULN or ? 5 × ULN for subjects with known hepatic metastases
Aspartate aminotransferase > 100 IU/L
Aspartate aminotransferase (AST) ?3 × ULN
Aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) =< 1.5 X ULN
Aspartate aminotransferase (AST) =< 2.5 x the ULN (in the absence of hepatic involvement of tumor)
Aspartate aminotransferase (AST) =< 3 times ULN
Aspartate aminotransferase (AST) and ALT < 3.0 × ULN
Aspartate aminotransferase (AST) =< 3 times ULN
Aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) < 5 x ULN
Aspartate aminotransferase (AST) < 5.0 x ULN
Aspartate aminotransferase (AST) =< 2 x institutional ULN
Aspartate aminotransferase level (AST) =< 3 x ULN, within 30 days prior to enrollment
Obtained within 28 days prior to registration: Aspartate aminotransferase (AST) =< 2.5 x ULN (subjects with documented liver metastases should have AST =< 5 x ULN)
Aspartate aminotransferase (AST) < 3 × ULN unless hepatic metastases are present, then < 5 × ULN
Aspartate aminotransferase (AST) < 5 X institutional ULN
Aspartate aminotransferase (AST) =< 1.5 x ULN
Aspartate aminotransferase (AST) > 3 x ULN
Aspartate aminotransferase =< 45 IU/dL
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x ULN for patients with documented liver metastases)
Obtained within 28 days prior randomization: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be =< 3 x ULN for the lab with the following exception: for patients with documented liver metastases, AST and ALT must be =< 5 x ULN
Aspartate aminotransferase (AST) ? 2.5 × ULN without liver metastases; must be ? 5 × ULN with liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULN or ? 5 × ULN for patients with liver metastases
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastasis) (=< 28 days prior to registration)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN (or =< 5.0 x ULN if liver metastases are present)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (unless elevated transaminases are felt to be directly related to metastatic disease involving the liver, in which case AST and ALT must be =< 5 x ULN) must be met within 28 days of C1D1
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x the institutional ULN\r\n* Note that physician attestation of patient having no known history of liver disease can take the place of bilirubin and AST/ALT labs
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 x ULN; if liver metastases are present, then ? 5 x ULN is allowed.
Serum transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) =< 2.5 x ULN in the absence of liver metastases and =< 5 x ULN in case of liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN; for patients with hepatic metastases, ALT and AST =< 5 x ULN
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST) < 2.5 x ULN; if liver metastases, ALT/AST =< 5.0 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)
Alanine aminotransferase or aspartate aminotransferase < 2.5 x the ULN or < 5 x the ULN if secondary to liver metastasis
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN (or =< 5 x ULN for subjects with liver metastasis)
Alanine aminotransferase (ALT)/aspartate aminotransferase (AST), should be less than or equal to 1.5 x ULN (CTCAE v4.0, grade 1); for patients with liver metastases, ALT/AST should be less than or equal to 2.5 x ULN (CTCAE v4.0 grade 1)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN; AST and ALT ? 5 × ULN for patients with liver metastasis
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; if the patient has liver metastases, ALT and AST must be =< 5 x ULN.
Within 10 (except as noted) days of planned treatment initiation: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x institutional ULN OR =< 5 x ULN for patients with known liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN or < 5 x ULN if liver metastases
PHASE II INCLUSION CRITERIA: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN or < 5 x ULN if liver metastases
Aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase =< 2.5 x ULN, or =< 5 x ULN in subjects with liver metastases within 28 days of treatment initiation and must be independent of hematopoietic growth factor support
In the absence of liver metastases, alanine aminotransferase (AST) and aspartate aminotransferase (ALT) should be below 3.0 × ULN. If the participant has liver metastases, ALT and AST should be below 5.0 × ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x ULN or < 5 x the ULN if liver metastasis performed within 30 days prior to the date of registration
alanine aminotransferase /aspartate aminotransferase (ALT/AST) ?2.5 x ULN without, and ? 5 x ULN with hepatic metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN or =< 5 x ULN for patients with liver metastases within 8 weeks of pre-registration
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x ULN if liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 ULN or =< 5 x ULN if liver mets are present
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ?2.5 × institutional ULN OR ?5 × institutional ULN for participants with liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) at =< 2.5 x ULN (in case of liver metastasis AST/ALT at =< 5.0 x ULN)
Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) =< 2.5 x ULN (or =< 5 x ULN if liver metastases are present)
Patients are eligible with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 3 x ULN; (up to 5 x ULN if liver metastases present)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastasis, =< 5 times for patients with liver metastases
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 X ULN (or < 5 x ULN with liver metastases)
Aspartate aminotransferase (AST) and alanine-aminotransferase (ALT) levels =< 2.5 x ULN or, for patients with documented metastatic disease to the liver, AST and ALT levels =< 5 x ULN
Aspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x ULN if judged by the investigator to be related to liver metastases
Alanine aminotransferase and aspartate aminotransferase =< 2.5 x ULN, (=< 5.0 x ULN with documented liver metastases) within 14 days prior to first dose of protocol-indicated treatment.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ?3x the ULN (?5x the ULN for subjects with liver metastases)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN, unless liver metastases are present, then values must be ? 5 x ULN)
Within 28 days prior to registration: Aspartate aminotransferase (AST) =< 2.5 x ULN (or =< 5 x ULN if liver metastases)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 times the ULN range of each institution. With the following exceptions: subjects with documented liver metastases; AST and ALT < 5 x ULN.
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x institutional ULN OR =< 5 x ULN for subjects with liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN, unless liver metastases are present, then values must be =< 3 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) ? 3 x institutional ULN (? 5 x ULN in the presence of liver metastases)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 3 x ULN (or ? 5.0 x ULN if hepatic metastases are present)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 4 x ULN for subjects with liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN, unless associated with hepatobiliary metastases, in that case =< 5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2 x ULN without liver metastasis; =< 5 x ULN with liver metastasis
Within 28 days prior to enrollment: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN except for subjects with liver mets for whom ALT and AST should be =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (results within 7 days before study drug administration), =< 5 x ULN for patients with liver metastases
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 x ULN (or > 5 x ULN for patients with concurrent liver metastasis)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels ? 2.5 × ULN or AST and ALT levels ? 5 x ULN for subjects with documented metastatic disease to the liver; patient with history of unconjugated hyperbilirubinemia with otherwise acceptable liver enzyme levels (as per above criteria) may have higher bilirubin levels
Performed within 14 days of treatment initiation: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases
Obtained within 14 days prior to the first study treatment (cycle 1, day 1): aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN with the following exception: 1) patients with documented liver metastases: AST and/or ALT =< 5 x ULN
Within 14 days of the first study treatment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN or AST and ALT levels =< 5 x ULN (for subjects with documented metastatic disease to the liver)
alanine aminotransferase (ALT, SGPT) and aspartate aminotransferase (AST, SGOT) ? 2.5 x ULN (? 5 x ULN if liver metastases are present);
AST (aspartate aminotransferase) =< 2 x ULN\r\n* NOTE: ALT and/or AST may be =< 5 x ULN if due to liver metastases. If ALT or AST is > 2 and =< 5 x ULN in patients with liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional ULN (=< 5 x institutional ULN if there is liver metastasis)
Determined within 3 weeks of treatment initiation: Aspartate aminotransferase (AST) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 3 x ULN (> 5 x ULN if liver metastases are present)
Aspartate aminotransferase (AST), level =< 2.5 x ULN, and an alanine aminotransferase (ALT) level =< 2.5 x ULN or, for subjects with documented metastatic disease to the liver, AST and ALT levels =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN unless liver metastases are present, in which case it must be =< 5 x ULN.
Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ? 2.5 x ULN or ? 5x ULN if known liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN if no demonstrable liver metastases or =< 5 x ULN in the presence of liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (ALT and AST =< 5 x ULN is acceptable if liver metastases are present)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN or =< 5 x ULN if liver metastases are present
In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) should be below 2.5 × ULN. If the patient has liver metastases, ALT and AST should be < 5 × ULN.
Alanine aminotransferase (ALT) =< 1.5 x ULN, aspartate aminotransferase (AST) =< 1.5 x ULN); ALT and AST =< 5 x ULN if documented liver metastases
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT):\r\n* > 2.5 x ULN\r\n* > 5 x ULN, if liver metastasis present
Aspartate aminotransaminase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 5.0 x ULN if liver metastases present
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; for subjects hepatic metastases, ALT and AST =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN; if liver metastases are present, then AST and ALT =< 5 x ULN
Transaminases (aspartate aminotransferase-AST and alanine aminotransferase ALT) =< 2.5 x ULN (=< 5 x ULN if liver metastases are present)
Aspartate aminotransferase and/or alanine aminotransferase =< 3 x ULN (=< 5 x ULN if liver metastases are present) within 30 days prior to C1D1
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (or =< 4.0 x ULN if hepatic metastases are present)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN; for patients with liver metastases: AST/ALT > 5 x ULN
Aspartate aminotransferase (AST) =< 2.5 x ULN; =< 5 x ULN if liver metastases are present
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 10 x ULN, unless related to ALL liver infiltration
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (or =< 5.0 x ULN if hepatic metastases are present)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN or =< 5 x ULN for subjects with liver metastases
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 5 x ULN, except patients who are assigned to receive docetaxel must have liver function tests (serum transaminases, bilirubin) that are within 1.5 x the ULN
Must be met within 28 days of C1D1: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x UNL (unless elevated transaminases are felt to be directly related to metastatic disease involving the liver, in which case AST and ALT must be =< 5 x ULN)
Alanine transaminase (ALT) and aspartate aminotransferase (AST) < 1.5 x ULN (< 5 x ULN if patient has liver metastasis)
aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be less than or equal to 1.5 x ULN for the lab or less than or equal to 5 x ULN if liver metastasis.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases are present
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN; AST/ALT =< 5 x ULN if liver metastasis is present (to be performed within 7 days prior to start of study treatment)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases are present
Within 14 days of enrollment: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 x ULN, unless there are liver metastases in which case AST and ALT or > 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (in the case of liver metastases, =< 5 x ULN)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN for patients without liver metastasis, =< 5 x ULN for liver metastases
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 × ULN or < 5 × ULN in the setting of liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN without liver metastases (or ? 5 x ULN if liver metastases are present)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN (? 5 x ULN for subjects with liver metastases)
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.5 x institutional ULN or =< 5 x the institution ULN in the presence of known liver metastases
Aspartate aminotransferase (AST) =< 2.5 x ULN; note: if the patient has liver metastases present, then =< 5 x ULN
Hepatic: bilirubin <1.5 X ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2.5 X ULN. Patients with known liver metastases or liver neoplasms: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5.0 X ULN
Within 14 days prior to randomization: Aspartate aminotransferase (AST) and alanine aminotransaminase (ALT) must be =< 2.5 x ULN for the lab or =< 5 x ULN for patients with liver metastases.
Within 14 days of first dose of study drug: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN; if liver metastases, then =< 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) must be =< 2.5 x ULN, except if the elevations are due to hepatic metastases, in which case ALT and AST must be =< 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN OR < 5 x ULN if patient has liver metastasis
Within 14 days prior to first dose of study drug treatment: Aspartate aminotransferase (AST), alanine aminotransferase (ALT) =< 3 x ULN with the following exceptions:\r\n* Patients with documented liver metastases: AST and/or ALT =< 5 x ULN
Aspartate aminotransferase (AST) ? 3 x ULN OR ? 5 x ULN (if liver metastases present)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN unless liver metastases are present, in which case it must be =< 5x ULN.
Aspartate aminotransferase (AST), alanine aminotransferase (ALT) or alkaline phosphatase < 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN, obtained within 14 days prior to the first study treatment (cycle 1, day 1) with the following exception:\r\n* Patients with liver metastases may enroll with AST and ALT =< 5 x ULN
To be performed within 28 days prior to day 1 of protocol therapy: Aspartate aminotransferase (AST) =< 2.5 x ULN if no liver metastases or =< 5 x ULN if liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN (=< 5 x ULN for patients with documented liver metastases)
In absence of liver metastases, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN; if the patient has liver metastases, ALT and AST =< 5.0 x institutional ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, the AST/ALT =< 5 times ULN is acceptable
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2 x ULN unless related to metastatic breast cancer to the liver (in which case AST/ALT < 5 x ULN is allowed)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x ULN (=< 5 x ULN for patients with documented liver metastases)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) >= 3 x ULN (with or without liver metastasis [mets])
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN; in the setting of metastatic disease to the liver, AST/ALT may be =< 5 x ULN
Aspartate and alanine aminotransferase (AST & ALT) ?3.0 x ULN or ?5.0 x ULN if subject has liver metastasis;
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 times ULN (or 5.0 x ULN in the setting of liver metastases)
Aspartate aminotransferase (AST) =< 2.5 x ULN, or =< 5 x ULN if liver metastases are present
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 ULN if without liver metastases
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastases and =< 5 x ULN for patients with liver metastases
aspartate aminotransferase, alanine aminotransferase ? 2.5 X ULN, or ? 5.0 X ULN (if liver metastasis present)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN in the presence of liver metastases)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 5.0 x ULN if liver metastases present (within 14 days prior to day 1 of protocol therapy)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN, unless liver metastases are present, then values must be =< 3 x ULN)
Prior to cyclophosphamide and T cell infusions: aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x ULN (since all patients will have liver metastasis)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 1.5 X ULN; < 3 X ULN if known hepatic metastases =< 7 days prior to randomization
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) up to 2.5 x ULN if no liver metastases or ALT or AST up to 5 x ULN if liver metastases present
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN; for subjects with documented metastatic disease to the liver, AST and ALT levels =< 5 x ULN
Within 72 h of initiating study treatment: Aspartate aminotransferase (AST) =< 2.5 x ULN OR < 5 x ULN for liver metastases (mets)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< ULN (or =< 3 x ULN if liver involved with disease
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN, unless associated with hepatobiliary metastases, in that case =< 5 x ULN
Aspartate aminotransferase (AST) =< 3.0 X ULN (=< 5.0 X ULN if liver metastases are present)
Alanine aminotransferase (ALT), and aspartate aminotransferase (AST) =< 2.5 x ULN (for patients with liver metastases, =< 5 x ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 X ULN OR =< 5 X ULN for subjects with liver metastases
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastasis, =< 5 times for liver metastases
The aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must not be more than 2.5 x ULN within 72 hours prior to enrollment, or greater than 5.0 X ULN if in the Investigator’s judgment it is related to liver metastases; AST and ALT may be up to 5 x ULN within 72 hours prior to enrollment in participants with hepatic metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN unless associated with hepatic metastases, then ALT and AST ? 5 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels =< 2.5 x ULN or AST and ALT levels =< 5 x ULN (for subjects with documented metastatic disease to the liver)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN or =< 5 x ULN if caused by liver metastasis
Aspartate aminotransferase (AST) =< 2.5 x ULN, or =< 5 x ULN if liver metastases are present
No liver metastases: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN; liver metastases: AST and ALT =< 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN, or =< 5 x institutional ULN in subjects with liver metastasis
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN if liver metastases are present)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 2.5 x ULN (for patients with known liver metastasis, AST or ALT =< 3 x ULN is allowed) at the screening visit
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 1.5 x ULN (or < 5 x ULN if known liver metastases)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) > 2.5 x ULN (AST and ALT > 5 x ULN for subjects with liver metastasis)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN in the absence of liver metastases; AST and ALT =< 5 x ULN in the presence of liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (=< 5 x ULN in patients with liver metastases)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastasis
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN for institution or =< 5 x ULN for institution if clearly attributable to liver metastases
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT): ~ 2.5 x ULN for subjects without liver metastasis ~ 5 times for liver metastases
For subjects without liver metastases: alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5 x ULN if liver metastases are present)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)  =< 2.5 x ULN or =< 5.0 x ULN for subjects with liver metastases
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 x ULN (or =< 3 x ULN if liver involved with disease
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5.0 ULN in the presence of liver metastases)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (unless liver metastases, who can have AST/ALT =< 5 x ULN)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN (patients with documented liver metastases: AST and/or ALT =< 5 x ULN)
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 1.5 x ULN in pts without liver metastasis; for pts with liver metastasis: ALT or AST > 2.5 x ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT): =< 2.5 x ULN for subjects without liver metastasis; =< 5 times for liver metastases
Alanine aminotransferase (AST) or aspartate aminotransferase (ALT) > 3.0 x ULN (or < 5.0 x ULN if liver metastases are present)
Aspartate aminotransferase (AST) / alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN for patients with documented liver metastases)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 x ULN, or AST and ALT ? 5 x ULN if liver function abnormalities are due to underlying malignancy
Serum transaminases (alanine aminotransferase [ALT] and aspartate aminotransferase [AST]) ? 2.5 x ULN in the absence of liver metastases or =< 5 ULN in case of liver metastases)
Serum alanine aminotransferase/serum aspartate aminotransferase (ALT/AST) < 2.5 x ULN; for patients with liver metastases, ALT/AST < 5 x ULN is acceptable
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN (for subjects with liver metastases AST/ALT may be =< 5 x ULN)
Aspartate aminotransferase (AST) and alkaline phosphatase =< 2.5 x ULN (CTCAE v4.03 grade 1; AST and alanine aminotransferase [ALT] =< 3 x ULN [or =< 5.0 x ULN if hepatic metastases are present])
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 2.5 x institutional ULN unless metastatic to liver in which case AST and ALT should be < 5 x institutional ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN; for subjects with documented liver metastases, the AST/ALT may be =< 5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ? 3 x ULN (or < 5 x ULN in subjects with liver metastases or hepatocellular carcinoma).
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases are present
Alanine aminotransferase and AST ? 2.5 × ULN; for subjects with hepatic metastases, ALT and AST ? 5 × ULN
Alanine aminotransferase and aspartate aminotransferase =< 2.5 x ULN or =< 5.0 x ULN in case of documented hepatic metastasis
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 x ULN (ALT and AST =< 2.5 x ULN is acceptable if there is liver metastasis)
Hepatic: Direct bilirubin ?1.5 X ULN; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ? 2.5 X ULN. For patients with known liver metastases or liver neoplasms, then ALT or AST ? 5.0 X ULN is allowed
Aspartate aminotransferase (AST)/Alanine transferase (ALT) (SGOT/SGPT) < 2.5 x ULN for the reference laboratory or < 5 x ULN in the presence of liver metastases
Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ?2.5 X ULN (?5 x ULN in patients with liver metastases)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN (with or without liver metastases)
Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ? 2.5 x ULN or ? 5x ULN if known liver metastases
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x ULN or < 5 x ULN if known liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULN unless liver metastases are present, in which case they must be ? 5 × ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ? 2.5 × ULN unless liver metastases are present, in which case they must be ? 5× ULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) less than or equal to 2.5 x ULN unless liver metastasis is present then up to 5 X ULN permitted
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases are present
Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 5 X ULN in case of liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN if liver metastases are present)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastasis, =< 5 times for liver metastases
Aspartate aminotransferase (AST) =< 1.5 x ULN; alanine aminotransferase (ALT) and AST =< 3 x ULN is acceptable if there is liver metastasis
Have significant hepatic dysfunction (aspartate aminotransferase [AST]/alanine aminotransferase [ALT] >= 2 x ULN or reported liver disease)
Aspartate aminotransferase (AST) =< 2.5 x ULN OR < 5 x ULN for subjects with liver metastases, obtained within 14 days prior to C11-AMT PET scan
Abnormal liver functions consisting of any of the following:\r\n* Serum bilirubin >= 1.5 x ULN (except for patients with documented Gilbert’s disease)\r\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >= 2.5 x ULN, (for patients with known liver metastasis, AST or ALT =< 5 x ULN is allowed)
Aspartate amino transferase (AST or SGOT) and alanine amino transferase (ALT or SGPT) ? 1.5 × institutional ULN.
Aspartate amino transferase (AST) or alanine amino transferase (ALT) > 2.5 times the upper limit of normal (ULN).
Alanine amino transferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN (may not have abnormalities in both bilirubin and transaminases)
Obtained =< 21 days prior to registration: Alanine amino transferase (ALT) < 2.5 X ULN, with normal bilirubin; NOTE: Concomitant elevations in bilirubin and ALT above 1.5 x ULN (upper limit of normal) is not permitted
Within 3 weeks prior to study registration: \r\nAlanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) within 3 weeks prior to study registration
Aspartate amino transferase (AST) or Alanine amino transferase (ALT) >3 times ULN in patient without liver metastasis or liver cirrhosis
Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer or stent placement)
Aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Aspartate amino transferase (AST or serum glutamic oxaloacetic transaminase [SGOT]) and alanine amino transferase (ALT or serum glutamate pyruvate transaminase [SGPT]) =< 2.0 x institutional ULN
Aspartate amino transferase (AST) or alanine amino transferase (ALT) =< three times the upper limit of (institutional/central) normal (ULN) (if related to liver metastases =< five times ULN)
Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Aspartate amino transferase (AST) or alanine amino transferase (ALT) >= 2.5 times the upper limit of normal (if related to liver metastases >= five times the upper limit of normal)
Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) ? 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer) (obtained =< 7 days prior to randomization)
Alanine amino transferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN (tested within 14 days prior to registration)\r\n* Concomitant elevations in bilirubin and AST/ALT above 1.0 x ULN (upper limit of normal) are not permitted
Alanine amino transferase (ALT) and aspartate aminotransferase (AST) < 2.5 x ULN (upper limit of normal); concomitant elevations in AST/ALT above 1.0 x ULN are not permitted
Serum aspartate aminotransferase and alanine amino-transferase of at least 5 times the upper limit of normal
Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than 2.5 times the upper limit of normal (ULN), or AST or ALT greater than 5 times the ULN for those with Gilbert syndrome.
Aspartate amino transferase (AST) or alanine amino transferase (ALT) >= three (3) times the upper limit of normal
Alanine amino transferase (ALT) or aspartate amino transferase (AST) greater than 2.5 times the ULRR if no demonstrable liver metastases or greater than 5 times the ULRR in the presence of liver metastases.
Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN
Alanine aminotransferase (ALT) and aspartate amino-transferase (AST) =< 2.5 x ULN (=< 5 x ULN for subjects with liver involvement of their cancer)
Total bilirubin =< 1.5 X ULN (evaluated within 28 days of randomization); concomitant elevations in bilirubin and aspartate amino transferase (AST)/alanine aminotransferase (ALT) above 1.0 x ULN are not permitted
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 1.5 x institutional upper limit of normal (IULN) within 28 days prior to registration
Within 28 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 3 x IULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x institutional upper limit of normal (IULN) (or =< 5 x IULN if liver metastases are present)
Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN within 28 days prior to sub-study registration (if both ALT and AST are done, both must be =< 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5 x IULN (if both ALT and AST are done, both must be =< 5 x IULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 5 x institutional upper limit of normal (IULN) within 14 days prior to step 2 randomization
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or < 5 x IULN for patients with known liver metastases)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 5 x IULN within 28 days prior to registration
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (=< 5 x IULN secondary to lymphoma) within 28 days prior to registration
Obtained within 28 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or < 5 x IULN for patients with known liver metastases)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2 x IULN
Patients must have aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x institutional upper limit of normal (IULN) within 14 days prior to registration
AST/ALT =< 2.5 x the IULN or =< 5 x IULN for patients with liver metastases
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x institutional upper limit of normal (IULN) except for Gilbert’s disease or when in the opinion of treating physician elevated levels are due to direct involvement of leukemia (e.g., hepatic infiltration or biliary obstruction due to leukemia), in which case ALT and AST may be elevated up to =< 5 x IULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x IULN
ALT and AST 2.5-5 x IULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x IULN
Alanine aminotransferase (alanine aminotransaminase [ALT]) and aspartate aminotransferase (aspartate aminotransaminase [AST]) ? 2.5 x IULN
Obtained within 14 days prior to enrollment: aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase (ALP) =< 3 x institutional upper limit of normal (IULN) without liver mets or =< 5 x IULN with liver metastases
Serum aspartate aminotransferases (AST) or alanine aminotransferases (ALT) < 2.5 x IULN for patients without liver metastases; for patients with liver metastases AST or ALT < 5 x IULN is allowed
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) of less than 3 X IULN
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x IULN
Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN within 28 days prior to Step 2 re-registration (if both ALT and AST are done, both must be =< 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5 x IULN (if both ALT and AST are done, both must be =< 5 x IULN)
Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN within 28 days prior to Step 2 re-registration (if both ALT and AST are done, both must be =< 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5 x IULN (if both ALT and AST are done, both must be =< 5 x IULN)
Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN within 28 days prior to step 2 re-registration (if both ALT and AST are done, both must be < 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5 x IULN (if both ALT and AST are done, both must be =< 5 x IULN)
Alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 4 x institutional upper limits of normal (IULN)
Obtained within 28 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or =< 5 x IULN for patients with known liver metastases)
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) < 2.5 x IULN
Patients must have aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x IULN, unless due to lymphoma, within 42 days prior to registration
CLINICAL/LABORATORY CRITERIA: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or =< 5 x IULN for patients with known liver metastases); these results must be obtained within 28 days prior to registration
Total bilirubin =< 1.5 x IULN or =< 3.0 x IULN with normal aspartate aminotransferase (AST) and alanine aminotransferase (ALT) in patients with Gilbert’s disease
Either alanine aminotransferase (ALT) or aspartate aminotransferase (AST) =< 2 x IULN within 28 days prior to RE-TREATMENT registration (if both ALT and AST are done, both must be =< 2 IULN); for patients with liver metastases, either ALT or AST must be =< 5 x IULN (if both ALT and AST are done, both must be =< 5 x IULN)
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 2.5 x IULN
Within 14 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN; patients with liver metastases may have AST and ALT of =< 5.0 x IULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both =< 2.5 X IULN in the absence of liver metastases or =< 5.0 x IULN with liver metastasis
SGOT (AST) =< 3.0 x IULN and SGPT (ALT) =< 3.0 x IULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x IULN OR ALT and AST =< 5.0 x IULN for patients with documented hepatic involvement with NHL
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x institutional upper limit of normal (IULN) or =< 5 x IULN if liver metastases are present
AST and ALT =< 2.5 x IULN or =< 5 x IULN if liver metastases are present within 14 days prior to Step 3 registration
Patients must have adequate organ and bone marrow function prior to registration, as defined below: \r\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) < 2 x institutional upper         limit of normal (IULN)\r\n* Total bilirubin < 2.0 x IULN (unless Gilbert syndrome has been diagnosed); if leukemia infiltration of the liver is suspected to be causing liver function abnormalities the patient will still be eligible with principal investigator (PI) approval\r\n* Creatinine < 2 x IULN\r\n* Creatinine clearance > 40 mL/min (measured by Cockroft-Gault)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 institutional upper limit of normal (IULN) (=< 5 x IULN if liver metastases are present)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 × IULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x IULN (or < 5 x IULN for patients with known liver metastases)
Aspartate and alanine aminotransferase =< 2.5 x IULN, bilirubin =< 1.5x IULN
Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) or 3 x IULN with normal alanine aminotransferase (ALT) and aspartate aminotransferase (AST) in patients with Gilbert’s disease
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) both < 2.5 x IULN within 28 days prior to registration
Adequate baseline hematological and organ function, assessed by laboratory values prior to study treatment as follows: absolute neutrophil count (ANC) > 1.0 x 109/L; hemoglobin > 7 g/dL; serum creatinine < 2 x institutional upper limit of normal (IULN); aspartate transaminase (AST) < 2.5 x IULN; alanine transaminase (ALT) < 2.5 x IULN; (if liver metastases are present, ALT and AST < 5 x IULN); total bilirubin < 1.5 x IULN.
Must have alanine transaminase (ALT) ? 3 × institutional upper limit of normal (ULN) [? 5 × ULN in presence of liver metastases] within 14 days prior to randomization.
Alanine aminotransferase (ALT) ? 2.5 × ULN without liver metastases; must be ? 5 × ULN with liver metastases
ALT ?2.5 x ULN (if liver or bone metastases are present, ?5 x ULN)
Alanine transaminase (ALT) =< 3 x ULN, except for patients with liver metastasis, who are only included if ALT =< 5 x ULN, at the screening visit
Alanine aminotransferase ? 3 x ULN or ? 5 x ULN if liver metastasis is present.
Within 28 days prior to registration: Alanine aminotransferase (ALT) =< 2.5 x ULN (or =< 5 x ULN if liver metastases)
Alanine aminotransferase (ALT) within 2.5 x ULN unless there are liver metastases in which case, ALT within 5 x ULN
Alanine aminotransferase (ALT) within 2.5 x ULN unless there are liver metastases in which case, ALT within 5 x ULN
Determined within 3 weeks of treatment initiation: Alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases
Alanine aminotransferase (ALT) =< 2.5 x ULN (obtained within 28 days prior to first study treatment)\r\n* Subjects with documented liver metastases should have ALT =< 5 x ULN
Obtained =< 14 days prior to randomization: Alanine transaminase (ALT) =< 2.5 x ULN (=< 5 x ULN for patients with liver involvement)
If liver metastasis present, then AST/ALT =< 5 x ULN
CERITINIB INCLUSION CRITERIA: AST (SGOT) and ALT (SGPT) =< 3 x ULN if no liver metastases are present? =< 5 x ULN if liver metastases are present
REGORAFENIB INCLUSION CRITERIA: AST (SGOT) and ALT (SGPT) =< 2.5 x ULN if no liver metastases are present? =< 5 x ULN if liver metastases are present
ENTRECTINIB INCLUSION CRITERIA: AST (SGOT) and ALT (SGPT) =< 3.0 x ULN if no liver metastases are present? =< 5 x ULN if liver metastases are present
Alanine aminotransferase (ALT) =< 2.5 x ULN; =< 5 x ULN if liver metastases are present
Alanine transaminase (ALT) ?2.5 × ULN, or ?5 × ULN if leukemic infiltration of the liver is present
ARM B COHORT 2: AST and ALT =< 2 X ULN; if liver metastases are present then must be < 5 X the ULN
ARM B COHORT 3: AST and ALT =< 2 X ULN; if liver metastases are present then must be < 5 X the ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN; note: if the patient has liver metastases present, then =< 5 x ULN
Alanine aminotransferase (ALT) ? 3 x ULN OR ? 5 x ULN (if liver metastases present)
Liver function tests performed within 3 weeks prior to starting study therapy must have alanine aminotransferase and aspartate aminotransferase =< 2.5 x ULN (or =< 5 x ULN if liver metastases are present)
To be performed within 28 days prior to day 1 of protocol therapy: Alanine aminotransferase (ALT) =< 2.5 x ULN if no liver metastases or =< 5 x ULN if liver metastases
Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) but =< 5.0 x ULN in case of liver metastases; in the presence of liver metastases the liver isoenzyme fraction must be measured and liver isoenzyme fraction (absolute value) must be =< 2 x ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN, or =< 5 x ULN if liver metastases are present
Alanine aminotransferase (ALT) =< 3.0 x ULN for patients without liver metastases; for patients with liver metastasis ALT =< 5 x ULN is allowed
AST and ALT =< 2.5 x ULN (=< 5 x ULN if liver metastases are present) obtained =< 7 days prior to registration
Within 72 h of initiating study treatment: Alanine aminotransferase (ALT) =< 2.5 x ULN OR < 5 x ULN for liver mets
Alanine aminotransferase (ALT) =< 3.0 X ULN (=< 5.0 X ULN if liver metastases are present)
AST/ALT levels ? 2.5 x ULN, or ? 5 x ULN if liver metastases are present.
Alanine transaminase (ALT) =< 3 x ULN (=< 5 x ULN for patients with liver involvement)
Alanine aminotransferase (ALT) =< 2.5 x ULN for patients without liver metastases; for patients with liver metastasis ALT =< 5 x ULN is allowed
Alanine aminotransferase (ALT) =< 2.5 x ULN, or =< 5 x ULN if liver metastases are present
Alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases persist
ALT =< 2.5 x =< 5 x ULN if liver metastases persist
Alanine aminotransferase (ALT) =< 2 x upper limit of normal (ULN) or =< 5 x ULN if liver metastases present
Alanine aminotransferase ?3 × ULN for the reference lab (?5 × ULN for subjects with known hepatic metastases)
Alanine transaminase (ALT) ? 3 × institutional upper limit of normal (ULN) [? 5 × ULN in presence of liver metastases] within 14 days prior to randomization.
Alanine aminotransferase (ALT) =< 2.5 x ULN; if liver metastases are present, =< 5 x ULN
Alanine aminotransferase (ALT)? 3 x upper limit of normal (ULN) or ? 5x ULN if liver metastasis is present
Alanine aminotransferase (ALT) =< 2.5 x ULN or =< 5 x ULN if liver metastases persist
Alanine transaminase (ALT) > 3.0 x ULN, except for patients with liver metastasis who are excluded if ALT > 5.0 x ULN
Alanine aminotransferase (ALT) < 2.5 times ULN; in the case of known (radiological and/or biopsy documented) liver metastasis, ALT < 5.0 times ULN is acceptable; patients with > 3 liver metastases at enrollment will be excluded
Obtained within 28 days prior to registration: Alanine aminotransferase (ALT) =< 2.5 x ULN (subjects with documented liver metastases should have ALT =< 5 x ULN)
Alanine aminotransferase (ALT) < 3 × ULN unless hepatic metastases are present, then < 5 × ULN
Alanine aminotransferase (ALT) =< 2.5 x ULN OR < 5 x ULN for subjects with liver metastases, obtained within 14 days prior to C11-AMT PET scan
Alanine aminotransferase (ALT) =< 2.5 x ULN (=< 5.0 x in case of liver mets), within 2 weeks prior to study start
Alanine transaminase (ALT) =< 3 x ULN (=< 5 x ULN acceptable for pancreatic subjects with known liver metastasis only)
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) must be within the range allowing for eligibility, must be obtained < 2 weeks prior to randomization
Within less than or equal to 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 1.5 x institutional ULN, within 21 days prior to registration
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x ULN within 90 days prior to Step 1 registration
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN within 28 days prior to step 1 registration
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN within 28 days prior to step 3 registration
Aspartate aminotransferase (AST) =< 2.5 x ULN obtained within 14 days prior to registration
Alanine aminotransferase (ALT) =< 2.5 x ULN obtained within 14 days prior to registration
Obtained within 14 days prior to C1D1: Aspartate aminotransferase (AST) =< 3 x ULN
Obtained within 14 days prior to C1D1: Alanine aminotransferase (ALT) =< 3 x ULN
Obtained =< 2 weeks prior to registration: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3.0 x ULN (=< 5 x ULN if liver metastasis)
Obtained within 28 days prior to registration: Aspartate aminotransferase (AST) =< 5 x ULN
Obtained within 28 days prior to registration: Alanine aminotransferase (ALT) =< 5 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN, within 14 days prior to registration
OBTAINED =< 7 DAYS PRIOR TO REGISTRATION: Aspartate aminotransferase (AST) =< 2 x ULN
Obtained =< 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Aspartate aminotransferase (AST) =< 2.5 × ULN obtained within 14 days prior to initiating study treatment.
Alanine aminotransferase (ALT) =< 2.5 × ULN obtained within 14 days prior to initiating study treatment.
Obtained ? 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ? 2.5 x ULN
Obtained within 28 days prior to registration: Aspartate aminotransferase (AST) =< 3 x ULN
Obtained within 28 days prior to registration: Alanine aminotransferase (ALT) =< 3 x ULN
Obtained within 14 days prior to randomization/registration:  aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
Obtained within 28 days prior to the first dose of cabozantinib: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN.
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN, obtained within 7 days prior to first study treatment
Aspartate aminotransferase (AST) =< 2.5 x ULN (obtained within three days prior to study treatment)
Alanine aminotransferase (ALT) =< 2.5 x ULN (obtained within three days prior to study treatment)
Obtained within 21 days prior to randomization/registration: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN.
Within 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Obtained =< 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN or < 5 x ULN if liver involvement
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN within 14 days prior to Step 2 registration
Within 14 days prior to registration: Aspartate aminotransferase (AST), alanine aminotransferase (ALT), =< 3 x ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2 x upper limit of normal (ULN) obtained =< 14 days prior to registration\r\n* NOTE: if baseline liver disease, Child Pugh score not exceeding class A
Aspartate aminotransferase (aspartate transaminase [AST]) and alanine aminotransferase (alanine transaminase [ALT]) =< 2.5 x ULN OR =< 5 X ULN for patients with liver metastases (obtained =< 14 days prior to registration)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN, obtained =< 14 days prior to registration
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN should be obtained within 21 days prior to enrollment
Aspartate aminotransferase =< 2.5 x institutional ULN obtained within 14 days of first treatment
Alanine aminotransferase =< 2.5 x institutional ULN obtained within 14 days of first treatment
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN obtained within 14 days prior to randomization/registration
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN, obtained within 30 days of study registration
Aspartate aminotransferase (AST) =< 1.5 x ULN, obtained =< 14 days prior to registration
Within 14 days prior to registration: Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3.0 x ULN
Alanine aminotransferase (ALT) and aspartate transaminase (AST) =< 3 x ULN (=< 5 x ULN for patients with liver involvement), obtained =< 14 days prior to registration
Obtained =< 14 days prior to registration: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN
Within 14 days prior to registration: Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 3 x ULN
Obtained ? 14 days prior to registration: aspartate transaminase (AST) and alanine aminotransferase (ALT) ? 3 x ULN
Obtained =< 21 days prior to registration: Aminotransferase (ALT) =< 3.0 x ULN, =< 5.0 x ULN for patients with metastatic disease to the liver
Aspartate transaminase (AST) and alanine aminotransferase (ALT) =< 2.5 x ULN OR =< 5 x ULN for subjects with liver metastases obtained =< 28 days prior to registration
Aspartate aminotransferase (aspartate transaminase [AST]) =< 2.5 x ULN, obtained =< 7 days prior to registration
Alanine aminotransferase (alanine transaminase [ALT]) =< 2.5 x ULN, obtained =< 7 days prior to registration
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 3 x institutional ULN within 14 days prior to registration
ARM A: obtained =< 14 days prior to registration: \r\nAspartate aminotransferase (AST)/alanine aminotransferase (ALT) =< 5 x ULN
Obtained within 30 days prior to registration: Aspartate aminotransferase (AST) =< 1.5 x ULN
Obtained within 30 days prior to registration: Alanine aminotransferase (ALT) =< 1.5 x ULN
Obtained within 14 weeks prior to registration on study: alanine aminotransferase (ALT) or aspartate aminotransferase (AST) < 2 x ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 4.0 x ULN obtained within 14 days prior to registration
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 2.5 x upper limit of normal (ULN) obtained =< 14 days prior to registration
Obtained =< 21 days prior to registration: Alanine aminotransferase (ALT) =< 3 x institutional ULN
Obtained =< 7 days prior to registration: Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 3 x institutional ULN
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (obtained =< 14 days prior to registration)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN obtained =< 7 days prior to registration (=< 5 x ULN in patients with liver metastases)
Obtained within 14 days prior to initiation of treatment: Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) < 2.5 times ULN
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x ULN, obtained within 14 days of the first dose of study drug
Alanine aminotransferase (ALT) or aspartate transaminase (AST) =< 3 x upper limit of normal (ULN) obtained =< 30 days prior to registration
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 X ULN, obtained within 14 days prior to PET scan
Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) > 2.5 x ULN obtained < 2 weeks prior to study enrollment
Alanine and aspartate aminotransferase (ALT/AST) =< 2.5 x upper limit of normal (ULN) obtained =< 14 days prior to registration
